Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 4/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.46 |
| ▸ | PTGES | O14684 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6458054 | 1.00 | CNR2 (0.53) | CNR2HCRTR1DPP4DPP7PTGES | |
| SCHEMBL30681561 | 0.82 | LMNA (0.62) | HCRTR1DPP4DPP7PTGESKCNH2 | |
| SCHEMBL1819622 | 0.82 | LMNA (0.62) | HCRTR1DPP4DPP7PTGESKCNH2 | |
| Hydrochloric Acid SCHEMBL6456796 | 0.81 | MCHR1 (0.51) | CNR2NPC1RAB9AMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL6456792 | 0.81 | MCHR1 (0.51) | CNR2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL6467380 | 0.79 | RAB9A (0.46) | HCRTR1NPC1RAB9AKMT2AGAA | |
| SCHEMBL6467378 | 0.79 | RAB9A (0.46) | HCRTR1NPC1RAB9AKMT2AGAA | |
| Hydrochloric Acid SCHEMBL6455812 | 0.79 | ADRA2A (0.60) | CNR2MAPTKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL6455820 | 0.79 | ADRA2A (0.60) | CNR2MAPTKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL6459870 | 0.78 | RAB9A (0.46) | HCRTR1NPC1RAB9AKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | claimed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | CNR2 52/4885HCRTR1 7/4885DPP4 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.